AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...
Gilead (GILD) stock won an upgrade from Deutsche Bank on HIV treatment boost, while Merck (MRK) stock received a downgrade on ...
Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...
Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...
In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...
We recently compiled a list of the Top 10 Stocks to Buy According to Lee Munder Capital Group. In this article, we are going ...
In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than Humira’s 20% at the same time point.
Proposed Medicaid cuts may create risks for biopharma, impacting drugs like AbbVie’s Humira and Gilead’s Biktarvy. Get access to your new suite of high-powered trading tools, including real ...
Humira net revenues decreased 48.7% on an operational basis to $1.682 billion, Skyrizi net revenues rose 57.9% to $3.778 billion, and Rinvoq revenues gained 47.1% to $1.834 billion. “We are ...
AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term ...